In June 2023, Renovaro announced that a potential IND application for its innovative cancer platform is on track for early 2024 FDA submission The company in March 2023 announced proof-of-concept for its proprietary technology to treat pancreatic tumors In August 2023, Renovaro announced its entry into a Letter of Intent to merge with GEDi Cube International Ltd. with the aim of accelerating diagnosis, enhancing treatment…
Genprex recently received a patent in China covering the use of its drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers The REQORSA-Keytruda drug combination is the subject of Genprex’s ongoing Acclaim-2 clinical trial, which targets patients with advanced, metastatic non-small cell lung cancer whose disease progressed after treatment with Keytruda The company has received patent protection for…
BiondVax, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, was featured in a recent analyst report reiterating a Buy recommendation and a $70 target price The report discussed Eli Lilly’s announcement of a definitive agreement to acquire DICE Therapeutics for approximately $2.4 billion as evidence of the potential value of BiondVax in this segment of the therapeutics market DICE Therapeutics is…
National awareness of glioblastoma tumors (“GBM”) sustained by Congressional leaders aim to improve efforts to treat brain cancers and ultimately improve patient survival GBM is a widely occurring, aggressive and effectively incurable brain cancer that few patients survive beyond three years U.S.-based drug developer CNS Pharmaceuticals is in the midst of a global potentially pivotal clinical trial for its lead pharmaceutical candidate, Berubicin, which it…
Reichman discusses BiondVax’s 2023 achievements, including the development of innovative NanoAbs in collaboration with the Max Planck Institute targeting interleukin-17 (IL-17) targeting diseases such as psoriasis Annual sales for current anti-interleukin-17 monoclonal antibodies now total about $7.5 billion annually – and BiondVax is positioned to penetrate this market with promising results Investor Brand Network (“IBN”) recently announced the release of its latest episode of The…
Genprex recently announced that its lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities in the Phase 1 portion of its Acclaim-1 clinical trial The Phase 1 clinical data were added to by the release of a new patient video highlighting a patient’s experience with REQORSA. This patient has now been on the Acclaim-1 trial without disease progression for one year The Safety…
BiondVax’s CDMO services allow the company to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services BiondVax showcased its boutique end-to-end CDMO offering at the annual Biomed Conference in Tel Aviv in May BiondVax’s cGMP biologics manufacturing facility in Jerusalem is fully equipped with state-of-the-art CDMO capabilities The expansion of CDMO services will augment revenue and expand pharma contacts while still maintaining…
Genprex Chief Medical Officer, Dr. Mark Berger, was featured in a recent Bell2Bell Podcast episode, where he discussed the company’s recent announcements In May, the company received Safety Review Committee (“SRC”) approval to advance to the Phase 2 expansion portion of its Acclaim-1 clinical trial of its lead candidate, REQORSA(R) Immunogene Therapy The Phase 1 dose escalation portion of the study showed that REQORSA(R) was…
BiondVax just signed an exclusive worldwide license agreement with the Max Planck Society to develop and commercialize innovative NanoAb therapeutics for the treatment of psoriasis and psoriatic arthritis Part of an ongoing broad-based collaboration targeting therapies addressing diseases such as Covid-19, asthma, and macular degeneration Per BiondVax’s CEO, Amir Reichman, this exclusive license presents an exciting opportunity to develop a unique treatment for psoriasis BiondVax…
Biotechnology company BiondVax has entered into a collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) to develop innovative NanoAbs BiondVax enjoys an exclusive option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized thereunder the RCA The company recently announced intent to develop innovative NanoAbs targeting immune system cytokines such…
U.S.-based gene therapy developer Genprex, Inc. is dedicated to finding more effective and novel solutions for battling cancer (particularly lung cancers) and diabetes Genprex utilizes a propriety platform that encapsulates tumor-suppressing genes within lipid nanoparticles that are injected intravenously The company has received Fast Track designation from the U.S. Food and Drug Administration (“FDA”) for its two non-small cell lung cancer (“NSCLC”) programs using its…
Biotechnology innovator BiondVax Pharmaceuticals is dedicated to developing nanosized antibody (NanoAb) treatment BiondVax is also leveraging its team experience in preclinical stage to Phase 3 clinical trial product development to generate new revenues by offering cGMP contract development and manufacturing organization (“CDMO”) services The company recently exhibited its CDMO expertise as well as its NanoAb development pipeline at the 21st annual Biomed Israel conference, which…
Gene Therapy's Transformative Potential Highlighted in Inspiring Patient Video Interview with Genprex’s (NASDAQ: GNPX) REQORSA on Benzinga. Click Here for the full article The interview showcases the real-life experience of a patient participating in a clinical trial utilizing Genprex's innovative gene therapy drug candidate, REQORSA, shedding light on the significant impact it could potentially have in advancing the treatment of non-small cell lung cancer. The…
Analysts at Aegis Capital Corp. continue to recommend shares of the company with a Buy rating and a $70 target price Data from pre-clinical trial indicate that BiondVax’s NanoAb may effectively serve as both a therapeutic and protective prophylactic drug, further enhancing its value proposition BVXV reiterated further NanoAb development beginning with NanoAbs targeting immune system cytokines such as IL-17 as drug candidates for the…
NextPlat inks deal to provide American businesses easy access to Chinese consumer market E-Commerce Development Program in collaboration with Tmall Global announced at Miami event Tmall Global e-commerce platform will provide NextPlat customers simple turnkey solution to sell products to the Chinese consumer market First in a series of new e-commerce development programs designed to provide US businesses swift, easy e-commerce access to new international…
Biotechnology innovator BiondVax Pharmaceuticals recently provided a business update and published full-year financial results for the period ended December 31, 2022 Achievements realized to date leave CEO Amir Reichman optimistic about the company’s growth potential and ability to deliver value to shareholders The company enjoys definitive, exclusive agreements including options for exclusive worldwide licenses with the Max Planck Society and the University Medical Center Göttingen,…
NextPlat, Tmall Global sign merchant sourcing agreement designed to give U.S. businesses easy access to Chinese e-commerce market. Tmall Global e-commerce platform will provide NextPlat customers a turnkey solution to sell products to the Chinese consumer market. Starting in Florida, NextPlat intends to expand E-Commerce Development Program businesses throughout the United States and all of the Americas. Turnkey international e-commerce solution simplifies the process, provides…
Positive preclinical data was presented for the NPRL2 tumor suppressor gene The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (“NSCLC”) humanized mouse models Validates ONCOPREX(R) platform’s ability to deliver other tumor suppressor genes to potentially address multiple types of cancer ONCOPREX(R) Nanoparticle Delivery System is the novel non-viral platform being used for the…
NextPlat is led by a highly experienced management team, board of directors and advisors with proven expertise in M&A, finance, e-commerce, media, technology and health care The company operates a state-of-the-art e-commerce platform serving customers in over 195 countries NextPlat recently announced a new e-commerce development program in collaboration with Alibaba’s Tmall Global to provide American businesses easy access to the Chinese consumer market, with…
BiondVax intends to expand its contract development and manufacturing organization (“CDMO”) offering as it continues the primary focus on its NanoAb pipeline development The CDMO services include aseptic fill and finish, upstream and downstream process development, as well as analytical model development and analytical testing This is made possible by BiondVax’s state-of-the-art assets in Jerusalem, Israel, including GMP-ready production clean rooms, fermentors, WFI, analytic tools,…
RMXD news indicates that a synergistic tech-healthcare collaboration with potential to ignite both growth and revenues is in the works “Restructuring whiz” takes the helm as CEO, board chair Through technology and proven processes, Progressive Care helps simplify chaos, improve care and reduce costs Recent developments bode well for the future of Progressive Care (OTCQB: RXMD). On a mission to snag ever more market share…
The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK, and Bristol-Myers Squibb The team has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza candidate, and built, owns, and operates its GMP biologics manufacturing facility BiondVax has an exclusive collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and…
BiondVax participated in the life science industry’s 17th annual Bio-Europe Spring Conference, held this year in Switzerland BiondVax was highlighted as one of the “best ideas” in a NASDAQ-published article after the completion of the conference The company’s biobetter nanosized antibody therapies promise stability at high temperatures, superior binding affinity, convenient routes of administration, and cost effective production The EBD Group’s 17th annual Bio-Europe Spring…
BiondVax Pharmaceuticals is a biotechnology company developing, manufacturing, and commercializing innovative NanoAb immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases Company CEO Amir Reichman recently presented at the BIO-Europe Spring conference, where he talked about BiondVax’s successful preclinical in vivo results of its innovative inhaled COVID-19 treatment and additional pipeline plans The in vivo results have shown that the company’s inhaled…
Glioblastoma (“GBM”), an aggressive and generally fatal brain cancer, has attracted attention as a significant unmet medical need because of its incurability, claiming the lives of more than 200,000 patients worldwide each year CNS Pharmaceuticals is in the middle of a potentially pivotal global Phase 2 clinical trial for its drug candidate, a novel anthracycline called Berubicin that is apparently unique in its ability to…
CNS Pharmaceuticals recently announced it had enrolled the first patient in Switzerland as part of its ongoing potentially pivotal global GBM trial The adaptive, multicenter, open-label, randomized controlled trial is evaluating Berubicin for the treatment of recurrent GBM, the most common primary brain cancer, compared to Lomustine, the current standard of care The enrollment moves the company closer to its goal of undertaking an interim…
Restructuring whiz takes helm at RXMD New CEO takes no salary or other forms of compensation Company sees infusion of $6 million cash from key investors A synergistic tech-healthcare collaboration grows as financials show upward trend Looks like something big is brewing at Florida-based Progressive Care (OTCQB: RXMD). Focused on health services, the company offers healthcare services and technology that supports the managed healthcare industry…
CNS recently enrolled the first patient in Spain in its ongoing global trial evaluating its lead drug candidate, Berubicin, for the treatment of recurrent glioblastoma multiforme (“GBM”) This milestone is the culmination of years of meticulous planning and execution The enrollment of this first patient follows the opening of 37 clinical trial sites of the 59 sites selected across the United States, Italy, France, Spain…
Net revenue increased 133% to $332,000 in the three months ended Dec. 31, 2022, the company reports Corporate highlights included expanded trial sites, enrollment for phase 2 IGC-AD1 study Commencement of study marks milestone in IGC’s progress toward gaining FDA approval for proprietary treatment In a fragile economic environment, the third-quarter 2023 financial results reported by India Globalization Capital (NYSE American: IGC) are particularly remarkable.…
New data show rising burden of most cardiovascular risk factors among young adults aged 20 to 44 in the U.S. Findings are “extremely concerning” as expert notes “we’re witnessing a smoldering public health crisis” HeartBeam has developed the first and only 3D-vector electrocardiogram for heart attack detection anytime, anywhere A recent study shows that risk factors for cardiovascular (“CV”) disease are rising among young adults…
Progressive Care reported a 4% year-over-year revenue increase to approximately $10.1 million for the quarter ended September 30, 2022 The company’s prescription revenue increased 16% year-over-year to almost $9.4 million during that same period In 2022, Progressive Care received nearly $6 million from a strategic investment transaction with NextPlat Corporation The company launched its ClearMetrX platform for 340B third-party administration in 2022 Progressive Care will…
A recent medical study found that psychedelic drugs showed promise as a treatment alternative for hard-to-treat depression Psychedelics were found to activate a greater number of serotonin 2A receptors then traditional antidepressant drugs, largely because of their ability to penetrated through cells’ fatty outer membranes The study reinforces the potential use of psychedelic drugs, and psilocybin in particular, as a treatment methodology for a variety…
BiondVax is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, primarily for the treatment of infectious and autoimmune diseases The company is led by CEO Amir Reichman, with over 20 years of international experience as a biopharma expert Amir took company reins in 2021 and pivoted the mission and vision including diversifying risks With new focus and opportunity, BiondVax now developing…
Government showing strong support for bills aimed at treating Alzheimer’s disease IGC’s leading drug candidate recently completed phase 1 of a safety and tolerability trial, and entered phase 2 Company’s proprietary treatments have “the potential to revolutionize the treatment of Alzheimer’s disease” Key legislation designed to fight Alzheimer’s has been introduced in Congress — or actually reintroduced: the NAPA Reauthorization Act was first introduced in…
During interview, Vajdic recounts first steps of journey in the United States CEO points to key lessons he learned that helped him found HeartBeam The company has developed the first and only 3D-vector 12-lead electrocardiogram (“ECG”) platform for heart attack detection anytime, anywhere Growing up in Yugoslavia (now Serbia) as the only child of a well-known surgeon, HeartBeam (NASDAQ: BEAT) CEO and founder Branislav Vajdic,…
BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products The company’s alpaca-derived nanosized antibodies (“NanoAbs”) exhibit superior valuable competitive advantages over commercially available monoclonal antibodies (“mAbs”), including better specificity and affinity to the target, hyper-thermostability, and potential for more effective and convenient routes of administration Preclinical in vivo data have shown its lead drug candidate, the inhaled anti-SARS-CoV-2 NanoAb,…
BiondVax is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products The company primarily targets infectious diseases and autoimmune diseases, with its lead candidate, an inhaled COVID-19 NanoAb therapy, the subject of preclinical studies So far, the preclinical studies have shown that the NanoAb results in significantly milder illness and faster recovery, eliminates the SARS-CoV-2 virus from the lungs, and prevents illness…
SILO issued US Patent by USPTO titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females” Claims allowed by patent protect use of SPC-15 for treating stress-induced affective disorders, including anxiety and PTSD Other therapeutics in company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, SPC-14 to treat Alzheimer’s disease Therapeutics developed by SILO may qualify for FDA’s streamlined 505(b)(2) regulatory drug…
BiondVax Pharmaceuticals is promoting preclinical results of its lead “biobetter” NanoAb drug candidate for conveniently proactively preventing COVID The company’s CEO recently presented the data at the annual BIO CEO & Investor Conference in New York, as well as updates on the company’s pipeline for treating autoimmune diseases such as psoriasis, asthma, psoriatic arthritis and macular degeneration Monoclonal antibody-based drug product Evusheld recently lost its…
President Biden proclaims February as American Heart Month Annual tradition provides opportunity to focus on nationwide problem of heart and blood-vessel diseases HeartBeam is committed to being part of the solution for identifying, treating heart attacks Following a decades-long tradition, President Joseph Biden issued a proclamation from the White House declaring February as American Heart Month (https://ibn.fm/6Z9Iq). This nationwide focus on heart health is fully…
To distribute a release in the next 24 hours. Contact our client services team.
Distribute a press release. Submit your release to get started.
Set up a Live demonstration. Schedule a date and time that works for you.
All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.
Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).